3020 J ournal of Medicinal Chemistry, 2001, Vol. 44, No. 18
Vlieghe et al.
(10) Yarchoan, R.; Broder, S. Anti-retroviral therapy of AIDS and
related disorders: general principles and specific development
of dideoxynucleotides. Pharmacol. Ther. 1989, 40, 329-348.
(11) Furman, P. A.; Fyfe, J . A.; St. Clair, M. H.; Weinhold, K.;
Rideout, J . L.; Freeman, G. A.; Nusinoff-Lehrman, S.; Bolognesi,
D. P.; Broder, S.; Mitsuya H.; Barry, D. W. Phosphorylation of
3′-azido-3′-deoxythymidine and selective interaction of the 5′-
triphosphate with HIV reverse transcriptase. Proc. Natl. Acad.
Sci. U.S.A. 1986, 83, 8333-8337.
(12) Hao, Z.; Cooney, D. A.; Hartman, N. R.; Perno, C. F.; Fridland,
A.; De Vico, A. L.; Sarngadharan, M. G.; Broder, S.; J ohns, D.
G. Factors determining the activity of 2′,3′-dideoxynucleosides
in suppressing human immunodeficiency virus in vitro. Mol.
Pharmacol. 1988, 34, 431-435.
(13) Balzarini, J .; De Clercq, E. Nucleoside and nonnucleoside reverse
transcriptase inhibitors active against HIV. In Textbook of AIDS
Medicine; Merigan, T. C., Bartlett, J . G., Bolognesi, D., Eds.;
Williams and Wilkings: Baltimore, 1999; pp 815-847.
(14) Cheng, Y. C.; Dutschman, G. E.; Bastow, K. F.; Sarngadharan,
M. G.; Ting, R. Y. C. HIV reverse transcriptase. General
properties and its interactions with nucleoside triphosphate
analogues. J . Biol. Chem. 1987, 262, 2187-2189.
(15) Fischl, M. A.; Richman, D. D.; Grieco, M. H.; Gottlieb, M. S.;
Volberding, P. A.; Laskin, O. L.; Leedom, J . M.; Groopman, J .
E.; Mildvan, D.; Schooley, R. T.; J ackson, G. G.; Durack, D. T.;
King, D. The efficacy of azidothymidine (AZT) in the treat-
ment of patients with AIDS and AIDS-related complex. A double
blind, placebo-controlled trial. N. Engl. J . Med. 1987, 317, 185-
191.
(16) Richman, D. D.; Fischl, M. A.; Grieco, M. H.; Gottlieb, M. S.;
Volberding, P. A.; Laskin, O. L.; Leedom, J . M.; Groopman, J .
E.; Mildvan, D.; Hirsch, M. S.; J ackson, G. G.; Durack, D. T.;
Nusinoff-Lehrman, S. The toxicity of azidothymidine (AZT) in
the treatment of patients with AIDS and AIDS-related complex.
A double blind, placebo-controlled trial. N. Engl. J . Med. 1987,
317, 192-197.
(17) Chariot, P.; Drogou, I.; De Lacroix-Szmania, I.; Eliezer-Vanerot,
M. C.; Chazaud, B.; Lombes, A.; Schaeffer, A.; Zafrani, E. S.
Zidovudine-induced mitochondrial disorder with massive liver
steatosis, myopathy, lactic acidosis, and mitochondrial DNA
depletion. J . Hepatol. 1999, 30, 156-160.
(18) Cohen, S. S. On the therapeutic use of nucleosides and the
penetrability of phosphorylated compounds. Biochem. Pharma-
col. 1975, 24, 1929-1932.
(19) Pe´rigaud, C.; Gosselin, G.; Imbach, J . L. Potentialite´s et ap-
plications the´rapeutiques d’analogues de nucle´osides. Ann. Inst.
Pasteur, Actual. 1992, 3 (no. 3), 179-215.
(28) Mansky, L. M.; Bernard, L. C. 3′-Azido-3′-deoxythymidine (AZT)
and AZT-resistant reverse transcriptase can increase the in vivo
mutation rate of human immunodeficiency virus type 1. J . Virol.
2000, 74, 9532-9539.
(29) Mourier, N.; Trabaud, C.; Graciet, J . C.; Simon, V.; Niddam, V.;
Faury, P.; Charvet, A. S.; Camplo, M.; Chermann, J . C.; Kraus,
J . L. Peptide-nucleoside conjugates: synthesis and anti-HIV
activities. Nucleosides Nucleotides 1995, 14, 1393-1402.
(30) Kimura, T.; Matsumoto, H.; Matsuda, T.; Hamawaki, T.; Akaji,
K.; Kiso, Y. A new class of anti-HIV agents: synthesis and
activity of conjugates of HIV protease inhibitors with a reverse
transcriptase inhibitor. Bioorg. Med. Chem. Lett. 1999, 9, 803-
806.
(31) Dessolin, J .; Galea, P.; Vlieghe, P.; Chermann, J . C.; Kraus, J .
L. New bicyclam-AZT conjugates: design, synthesis, anti-HIV
evaluation, and their interaction with CXCR-4 coreceptor. J .
Med. Chem. 1999, 42, 229-241.
(32) Matsumoto, H.; Hamawaki, T.; Ota, H.; Kimura, T.; Goto, T.;
Sano, K.; Hayashi, Y.; Kiso, Y. ‘Double-drugs’-A new class of
prodrug form of an HIV protease inhibitor conjugated with a
reverse transcriptase inhibitor by a spontaneously cleavable
linker. Bioorg. Med. Chem. Lett. 2000, 10, 1227-1231.
(33) Aggarwal, S. K.; Gogu, S. R.; Rangan, S. R. S.; Agrawal, K. C.
Synthesis and biological evaluation of prodrugs of zidovudine.
J . Med. Chem. 1990, 33, 1505-1510.
(34) Chu, C. K.; Bhadti, V. S.; Doshi, K. J .; Etse, J . T.; Gallo, J . M.;
Boudinot, F. D.; Schinazi, R. F. Brain targeting of anti-HIV
nucleosides: synthesis and in vitro and in vivo studies of
dihydropyridine derivatives of 3′-azido-2′, 3′-dideoxyuridine
and 3′-azido-3′-deoxythymidine. J . Med. Chem. 1990, 33, 2188-
2192.
(35) Tadayoni, B. M.; Friden, P. M.; Walus, L. R.; Musso, G. F.
Synthesis, in vitro kinetics, and in vivo studies on protein
conjugates of AZT: evaluation as a transport system to increase
brain delivery. Bioconjugate Chem. 1993, 4, 139-145.
(36) Lefebvre, I.; Perigaud C.; Pompon, A.; Aubertin, A. M.; Girardet,
J . L.; Kirn, A.; Gosselin, G.; Imbach, J . L. Mononucleoside
phosphodiester derivatives with S-acyl-2-thioethyl bioreversible
phosphate-protecting group: intercellular delivery of 3′-azido-
2′,3′-dideoxythymidine 5′-monophosphate. J . Med. Chem. 1995,
38, 3941-3950.
(37) Meier, C.; De Clercq, E.; Balzarini, J . Nucleotide delivery from
cyclosaligenyl-3′-azido-3′-deoxythymidine monophosphates (cy-
closal-AZTMP). Eur. J . Org. Chem. 1940, 5, 837-846.
(38) Saboulard, D.; Naesens, L.; Cahard, D.; Salgado, A.; Pathirana,
R.; Velazquez, S.; Mc Guigan, C.; De Clercq, E.; Balzarini, J .
Characterization of the activation pathway of phosphoramidate
triester prodrugs of stavudine and zidovudine. Mol. Pharmacol.
1999, 56, 693-704.
(39) Schlienger, N.; Peyrottes, S.; Kassem, T.; Imbach, J . L.; Gosselin,
G.; Aubertin, A. M.; Pe´rigaud, C. S-acyl-2-thioethyl aryl phos-
photriester derivatives as mononucleotide prodrugs. J . Med.
Chem. 2000, 43, 4570-4574.
(40) Vlieghe, P.; Bihel, F.; Clerc, T.; Pannecouque, C.; Witvrouw, M.;
De Clercq, E.; Salles, J . P.; Chermann, J . C.; Kraus, J . L. New
3′-azido-3′-deoxythymidin-5′-yl O-(ω-hydroxyalkyl) carbonate
prodrugs: synthesis and anti-HIV evaluation. J . Med. Chem.
2001, 44, 777-786.
(41) Pochet, S.; Kansal, V.; Destouesse, F.; Sarfati, S. R. Alkylgly-
coside carbonates of 3′-azido-3′-deoxythymidine. Tetrahedron
Lett. 1990, 31, 6021-6024.
(42) Rich, D. H.; Sun, C. Q.; Vara Prasad, J . V. N.; Pathiasseril, A.;
Toth, M. V.; Marshall, G. R.; Clare, M.; Mueller, R. A.; House-
man, K. Effect of hydroxyl group configuration in hydroxyethyl-
amine dipeptide isosteres on HIV protease inhibition. Evidence
for multiple binding modes. J . Med. Chem. 1991, 34, 1222-1225.
(43) Romeo, S.; Rich, D. H. Stereoselective synthesis of protected
amino alkyl epoxides. Tetrahedron Lett. 1994, 35, 4939-4942.
(44) Roush, W. R.; Straub, J . A.; Van Nieuwenhze, M. S. A stereo-
chemically general synthesis of 2-deoxyhexoses via the asym-
metric allylboration of 2,3-epoxy aldehydes. J . Org. Chem. 1991,
56, 1636-1648.
(45) Zimmerman, T. P.; Mahony, W. B.; Prus, K. L. 3′-Azido-3′-deoxy-
thymidine. An unusual nucleoside analogue that permeates the
membrane of human-erythrocytes and lymphocytes by non
facilitated diffusion. J . Biol. Chem. 1987, 262, 5748-5754.
(46) Hansch, C.; Steward, A. R.; Anderson, S. M.; Bentley, D. The
parabolic dependence of drug action upon lipophilic character
as revealed by a study of hypnotics. J . Med. Chem. 1968, 11,
1-11.
(20) Roy, B.; Fontecave, M. Le me´tabolisme des nucle´osides et des
nucle´otides: implications dans la recherche de nouveaux agents
anti-VIH. Bull. Inst. Pasteur 1993, 91, 89-100.
(21) Groothuis, D. R.; Levy, R. M. The entry of antiviral and
antiretroviral drugs into the central nervous system. J . Neu-
rovirol. 1997, 3, 387-400.
(22) Girard, P. M.; Pegram, P. S.; Diquet, B.; Anderson, R.; Raffi, F.;
Tubiana, R.; Sereni, D.; Boerner, D. Phase II placebo-controlled
trial of fozivudine tidoxil for HIV infection: pharmacokinetics,
tolerability, and efficacy. J . Acquir. Immune Defic. Syndr. 2000,
23, 227-235.
(23) Pan-Zhou, X. R.; Cretton-Scott, E.; Zhou, X. J .; Xie, M. Y.;
Rahmani, R.; Schinazi, R. F.; Duchin, K.; Sommadossi, J . P.
Comparative metabolism of the antiviral dimer 3′-azido-3′-
deoxythymidine-P-2′,3′-dideoxyinosine and the monomers Zi-
dovudine and Didanosine by rat, monkey, and human hepato-
cytes. Antimicrob. Agents Chemother. 1997, 41 (11), 2502-2510.
(24) Trapnell, C. B.; Klecker, R. W.; J amisdow, C.; Collins, J . M.
Glucuronidation of 3′-azido-3′-deoxythymidine (Zidovudine) by
human liver-microsomes. Relevance to clinical pharmacokinetic
interactions with Atovaquone, Fluconazole, Methadone, and
Valproic Acid. Antimicrob. Agents Chemother. 1998, 42 (7),
1592-1596.
(25) Pan-Zhou, X. R.; Cretton-Scott, E.; Zhou, X. J .; Yang, M. X.;
Lasker, J . M.; Sommadossi, J . P. Role of human liver P450s and
cytochrome b5 in the reductive metabolism of 3′-azido-3′-deoxy-
thymidine (AZT) to 3′-amino-3′-deoxythymidine (AMT). Biochem.
Pharmacol. 1998, 55, 757-766.
(26) Kellam, P.; Boucher, C. A. B.; Larder, B. A. Fifth mutations in
HIV-1 reverse transcriptase contributes to the development of
high-level resistance to zidovudine. Proc. Natl. Acad. Sci. U.S.A.
1992, 89, 1934-1938.
(27) Ren, J .; Esnouf, R. M.; Hopkins, A. L.; J ones, E. Y.; Kirby, I.;
Keeling, J .; Ross, C. K.; Larder, B. A.; Stuart, D. I.; Stammers,
D. K. 3′-Azido-3′-deoxythymidine drug resistance mutations in
HIV-1 reverse transcriptase can induce long range conforma-
tional changes. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 9518-
9523.